MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Bluebird Bio Inc

Gesloten

4.94 3.13

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.65

Max

4.96

Belangrijke statistieken

By Trading Economics

Inkomsten

32M

-29M

Verkoop

28M

39M

EPS

-2.84

Winstmarge

-74.536

Werknemers

248

EBITDA

20M

-40M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+32.92% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

9.6M

48M

Vorige openingsprijs

1.81

Vorige sluitingsprijs

4.94

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Bluebird Bio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 sep 2024, 16:08 UTC

Winsten
Acquisities, Fusies, Overnames

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

Peer Vergelijking

Prijswijziging

Bluebird Bio Inc Prognose

Koersdoel

By TipRanks

32.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.5 USD  32.92%

Hoogste 8 USD

Laagste 5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bluebird Bio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

1

Buy

4

Hold

0

Sell

Technische score

By Trading Central

3.72 / 3.82Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.